3 Residential Real Estate Developer, Pharmaceutical Company and Power Generation Company Stocks With a Strong Future Roadmap: Ashiana Housing, Ipca Laboratories and NTPC

Homebuilder, pharma and power producer stocks offer a focused view of a sector where demand keeps widening. Ashiana Housing, Ipca Laboratories and NTPC cover a residential real estate developer, a pharmaceutical company and a power generation company.

This list covers three homebuilder, pharma and power producer stocks with complete current figures: Ashiana Housing, Ipca Laboratories and NTPC. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Homebuilder, Pharma and Power Producer Stocks?

Homebuilder, pharma and power producer stocks are listed companies that develop residential homes and senior living projects, make formulations and active ingredients for India and global markets, and generate electricity from large coal, gas and renewable plants. Their earnings depend on housing demand, prescription demand and power consumption.

Homebuilder, Pharma and Power Producer Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing homebuilder, pharma and power producer stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Homebuilder, Pharma and Power Producer Stocks Have a Strong Roadmap in India?

Homebuilder, pharma and power producer stocks have a strong roadmap in India because steady demand for new homes, rising demand for quality medicines and growing electricity use keep widening the market for these companies.

• Housing developer. Buyers seek well planned homes.
• Pharma. Doctors prescribe trusted brands widely.
• Power generation. Factories and homes use more electricity.

Why Ashiana Housing Features Among These Homebuilder, Pharma and Power Producer Stocks

Among the homebuilder, pharma and power producer stocks on this list, Ashiana Housing develops mid-income residential projects and senior living communities in cities such as the Delhi region, Jaipur and Chennai. It is known for its focus on construction quality and timely delivery.

Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%.

The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P/E of 30.3, below the industry P/E of 30.7.

Roadmap: The company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.

What to watch: Track sales bookings, project launches and deliveries.

Why Ipca Laboratories Features Among These Homebuilder, Pharma and Power Producer Stocks

Among the residential project, medicine and electricity shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why NTPC Features Among These Homebuilder, Pharma and Power Producer Stocks

Among the three companies on this list, NTPC is India's largest power generation company, with thermal, hydro and renewable plants and a growing pipeline of green energy projects.

Revenue rose from Rs 134,994 crore in FY22 to Rs 189,799 crore in FY26, a compound annual growth rate of 8.9%. Net profit grew from Rs 15,474 crore in FY22 to Rs 30,010 crore in FY26, which works out to a compound annual growth rate of 18.0%.

In the June 2026 quarter, revenue grew 6.9% year on year to Rs 51,142 crore, while net profit rose 12.9% to Rs 6,896 crore. The company has a return on equity of 13.3%, a debt to equity ratio of 1.33 and a market capitalisation of Rs 292,694 crore. The stock trades at a P/E of 10.3, below the industry P/E of 21.3.

Roadmap: The company is adding thermal capacity to meet rising electricity demand while building a large renewable portfolio. Long-term power purchase agreements give it steady visibility.

What to watch: Follow capacity additions, renewable progress and plant availability.

Ashiana Housing vs Ipca Laboratories vs NTPC on Key Financials

The table below sets the three homebuilder, pharma and power producer stocks side by side on revenue, profit and margin, using reported figures.

Ipca Laboratories posts the highest return on equity in this group at 14.2%. NTPC has the largest FY26 revenue at Rs 189,799 crore, and Ashiana Housing shows the fastest revenue growth with a 50.2% compound annual rate. A useful habit with homebuilder, pharma and power producer stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Homebuilder, Pharma and Power Producer Stocks

Every theme carries risks that deserve a check before any decision. For these homebuilder, pharma and power producer stocks, the main points are:

• Housing cycles. Real estate and building demand can vary with rates and sentiment.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Fuel and power prices. Tariffs and fuel costs can influence earnings.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter homebuilder, pharma and power producer stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Homebuilder, Pharma and Power Producer Stocks

Homebuilder, pharma and power producer stocks reward patient research into demand, execution and financial strength. Ashiana Housing, Ipca Laboratories and NTPC each have a clear plan to grow. Based on the 11 November 2026 close, Ashiana Housing trades at Rs 355.6, Ipca Laboratories at Rs 1,938.4 and NTPC at Rs 327.

Download the Univest iOS App or Univest Android App to track homebuilder, pharma and power producer stocks, set price alerts and get research-backed stock ideas.

What are homebuilder, pharma and power producer stocks?

Ans. Homebuilder, pharma and power producer stocks are listed companies that develop residential homes and senior living projects, make formulations and active ingredients for India and global markets, and generate electricity from large coal, gas and renewable plants. Their earnings depend on housing demand, prescription demand and power consumption. This list looks at three of them, Ashiana Housing, Ipca Laboratories and NTPC, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which homebuilder, pharma and power producer stocks are covered in this list?

Ans. This list covers Ashiana Housing, Ipca Laboratories and NTPC. Based on the 11 November 2026 close, Ashiana Housing traded at Rs 355.6, Ipca Laboratories at Rs 1,938.4 and NTPC at Rs 327. Their return on equity ranges from 13.3% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.9% to 50.2%.

Why do homebuilder, pharma and power producer stocks have a strong future roadmap in India?

Ans. Homebuilder, pharma and power producer stocks have a strong roadmap in India because steady demand for new homes, rising demand for quality medicines and growing electricity use keep widening the market for these companies. The main drivers are as follows. Housing developer. Buyers seek well planned homes. Pharma. Doctors prescribe trusted brands widely. Power generation. Factories and homes use more electricity. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Ashiana Housing performed financially?

Ans. Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%. The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P/E of 30.3, below the industry P/E of 30.7. Looking ahead, the company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has NTPC performed financially?

Ans. Revenue rose from Rs 134,994 crore in FY22 to Rs 189,799 crore in FY26, a compound annual growth rate of 8.9%. Net profit grew from Rs 15,474 crore in FY22 to Rs 30,010 crore in FY26, which works out to a compound annual growth rate of 18.0%. In the June 2026 quarter, revenue grew 6.9% year on year to Rs 51,142 crore, while net profit rose 12.9% to Rs 6,896 crore. The company has a return on equity of 13.3%, a debt to equity ratio of 1.33 and a market capitalisation of Rs 292,694 crore. The stock trades at a P/E of 10.3, below the industry P/E of 21.3. Looking ahead, the company is adding thermal capacity to meet rising electricity demand while building a large renewable portfolio. Long-term power purchase agreements give it steady visibility.

What risks should investors check before buying homebuilder, pharma and power producer stocks?

Ans. Investors should check a few risks before buying homebuilder, pharma and power producer stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Regulatory approvals. Plant inspections and approvals can affect supplies. Fuel and power prices. Tariffs and fuel costs can influence earnings. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of homebuilder, pharma and power producer stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.